[Form 4] IMMUCELL CORP /DE/ Insider Trading Activity

ImmuCell Corporation director Kathy V. Turner received a grant of 17,899 non-qualified stock options.

Rhea-AI Filing Summary

ImmuCell Corporation director Kathy V. Turner received a grant of 17,899 non-qualified stock options. These options give her the right to buy an equal number of ImmuCell common shares at an exercise price of $7.60 per share and represent a compensation award rather than an open-market purchase.

The options vest over three years, with 5,966 options becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 options vesting on April 15, 2029. All of the options expire on April 15, 2036 if they are not exercised.

Insider Trade Summary

Grant/Award: 17,899 shares

Grant/Award 1 txn

Insider Turner Kathy V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	17,899	$0.00	$0.00

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 17,899 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmuCell (ICCC) disclose about Kathy V. Turner in this Form 4?

ImmuCell disclosed that director Kathy V. Turner received a grant of 17,899 non-qualified stock options. These options are compensation awards, giving her the right to buy ImmuCell common stock at a fixed exercise price according to a multi-year vesting schedule.

How many ImmuCell (ICCC) stock options were granted to Kathy V. Turner?

Kathy V. Turner was granted 17,899 non-qualified stock options. Each option represents the right to buy one share of ImmuCell common stock, subject to vesting conditions and an exercise price specified in the grant, as detailed in the Form 4 filing.

What is the exercise price of Kathy V. Turner’s ImmuCell (ICCC) stock options?

The stock options granted to Kathy V. Turner have an exercise price of $7.60 per share. This means she can purchase ImmuCell common stock at $7.60 once the options vest and before they expire, regardless of the market price at that future time.

How do Kathy V. Turner’s ImmuCell (ICCC) stock options vest over time?

The options vest in three annual tranches: 5,966 options become exercisable on April 15, 2027, another 5,966 on April 15, 2028, and 5,967 on April 15, 2029. Vesting must occur before she can exercise and purchase underlying common shares.

When do Kathy V. Turner’s ImmuCell (ICCC) stock options expire?

All 17,899 stock options granted to Kathy V. Turner expire on April 15, 2036. She must exercise any vested options before that expiration date; otherwise, the right to purchase ImmuCell common shares under this grant will lapse completely.

Are Kathy V. Turner’s ImmuCell (ICCC) option grants open-market purchases?

No. The Form 4 describes the transaction as a grant or award acquisition of stock options. This means the company awarded these options as compensation, rather than Turner buying shares or options directly on the open market from other investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turner Kathy V

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	$7.6	04/15/2026		A		17,899		(1)	04/15/2036	Common Stock	17,899	$0	17,899	D

Explanation of Responses:

1. The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.

Remarks:

The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)